26. (new) An HCV antibody according to claims 24 or 25 being a monoclonal antibody.

27. (new) An HCV antibody according to claim 24, further comprising a label.

28. (new) An HCV antibody according to claim 25, further comprising a label.

29. (new) An HCV antibody according to claim 26, further comprising a label.

30. (new) An HCV antibody according to claims 27 wherein said label is of the enzymatic, fluorescent or radioactive type.

31. (new) An HCV antibody according to claims 28 wherein said label is of the enzymatic, fluorescent or radioactive type.

32. (new) An HCV antibody according to claims 29 wherein said label is of the enzymatic, fluorescent or radioactive type.

33. (new) An HCV antibody according to any of claims 24-25 further being humanized by means of recombinant DNA technology.

34. (new) An HCV antibody according to any of claim 26 further being humanized by means of recombinant DNA technology.

35. (new) A kit for determining the presence of HCV antigens present in a biological sample, comprising,

(a) at least one monoclonal antibody according to any of claims 24-25 or 27-30,

(b) a buffer or components necessary or producing the buffer enabling the binding reaction between these antibodies and the HCV antigens present in said biological sample,

(c) a means for detecting the immune complexes formed in the preceding binding reaction.

36. (new) A kit for determining the presence of HCV antigens present in a biological sample, comprising,

(a) at least one monoclonal antibody according to any of claim 26,

(b) a buffer or components necessary or producing the buffer enabling the binding reaction between these antibodies and the HCV antigens present in said biological sample,

(c) a means for detecting the immune complexes formed in the preceding binding reaction.

37. (new) A kit for determining the presence of HCV antigens present in a biological sample, comprising,

(a) at least one monoclonal antibody according to any of claim 33,

(b) a buffer or components necessary or producing the buffer enabling the binding reaction between these antibodies and the HCV antigens present in said biological sample,

(c) a means for detecting the immune complexes formed in the preceding binding reaction.

38. (new) A humanized version of an HCV antibody according to any of claims 24-25 or 27-30.

39. (new) A humanized version of an HCV antibody according to any of claim 26.